Is There a Gene Therapy Trial for Wilson Disease I Can Join?

Gene therapy for Wilson disease is real and advancing, but it is not yet available as a treatment outside of specialised research settings. If you are hoping to enrol in a trial, the honest picture is: a small number of early-phase studies exist or have recently been completed, more are expected in the next few years, and whether you qualify depends heavily on your disease status, where you live, and the specific trial’s eligibility criteria. This post explains where the research stands and how to find out whether there is something open for you.

What gene therapy is trying to do

Wilson disease is caused by mutations in the ATP7B gene, which encodes a protein the liver uses to transport copper into bile for excretion.¹ Every current treatment — penicillamine, trientine, zinc — manages copper accumulation but does not fix the underlying gene. Gene therapy aims to deliver a functional copy of ATP7B directly into liver cells, restoring normal copper metabolism at the root cause.²

The most studied approach uses adeno-associated virus (AAV) vectors — modified viruses that carry the corrected gene into liver cells without integrating into the host genome in a way that causes harm. In preclinical mouse models of Wilson disease, AAV-delivered ATP7B corrected copper accumulation, prevented liver damage, and appeared safe over follow-up periods.² A CRISPR-based approach using nanoparticle delivery has also been explored in laboratory settings, though that remains further from clinical application.³

Where clinical trials currently stand

As of 2025, no large Phase 3 trial for a gene therapy in Wilson disease has been publicly announced or completed. However:

• Early-phase work building toward clinical trials has been reported, primarily from European and North American groups.²
• The investigational agent bis-choline tetrathiomolybdate (WTX101 / ALXN1840) — sometimes mistakenly called a “gene therapy” — is actually a new copper-chelating drug, not a gene therapy. It completed Phase 2 trials with encouraging results in newly diagnosed Wilson disease patients.⁴⁵ It has advanced toward regulatory review in some jurisdictions and represents the most clinically mature “new treatment” in the pipeline, though it works differently from gene therapy.
• True gene therapy trials require extensive safety validation before enrolling patients. AAV vectors carry their own risks (immune reactions, liver inflammation), and regulatory agencies require careful dose-escalation studies before broader enrolment.

The most reliable, up-to-date source for trials currently enrolling is ClinicalTrials.gov (https://clinicaltrials.gov). Searching for “Wilson disease gene therapy” or simply “Wilson disease” and filtering for “recruiting” status will show any currently open studies. The European equivalent is ClinicalTrialsRegister.eu.

How to check if you qualify

Every clinical trial publishes an eligibility criteria section. Common inclusion and exclusion factors for Wilson disease trials include:

Factor	Typical requirement
Age	Varies widely — some trials adult-only (≥18), some include adolescents
Disease status	Some trials want newly diagnosed patients; others want stable, treated patients
Liver function	Trials may exclude acute liver failure or end-stage cirrhosis
Current treatment	Some trials require stopping current chelation during the trial period
Geographic location	Most early trials are limited to specific countries or trial sites
Prior AAV exposure	Pre-existing antibodies against the AAV vector used may exclude you

The AAV pre-exposure point is worth understanding. Many people have natural antibodies to common AAV serotypes from prior infections. These antibodies can neutralise the gene therapy vector before it reaches liver cells, making treatment ineffective. Screening blood tests can determine whether you have high levels of these neutralising antibodies. If you do, you may be excluded from certain trials — though researchers are developing strategies to address this, including using less common AAV serotypes or immunosuppression protocols.

How to find and approach a trial

Step 1: Search ClinicalTrials.gov. Enter “Wilson disease” in the condition field and set status to “Recruiting” or “Not yet recruiting.” Review results for any gene therapy studies. If none appear for gene therapy specifically, note any investigational drug trials — these may still offer access to treatments not yet commercially available, such as WTX101.

Step 2: Contact your specialist. Your hepatologist or neurologist treating Wilson disease is your most important ally here. Academic medical centres — especially those with liver disease programmes — often know about trials before they appear on public registries, or can refer you to a centre running a trial.

Step 3: Reach out to patient organisations. The Wilson Disease Association (wilsondisease.org) maintains information on research developments and can sometimes connect patients with researchers looking for participants. Similar organisations exist in Europe and Australia.

Step 4: Ask about compassionate use or expanded access. If a trial has finished enrolling but is showing promising results, some jurisdictions allow patients to access the experimental treatment outside the formal trial through expanded access or compassionate use programmes. This requires application through your doctor.

Realistic expectations about timeline

Researchers are optimistic about gene therapy for Wilson disease, but “optimistic” in scientific development typically means years, not months. Moving from successful animal models to human trials, and then from Phase 1 safety studies to Phase 3 efficacy trials, and finally to regulatory approval, is a process that routinely takes 10 years or more.⁶ For patients who need treatment now, existing approved therapies — chelation with penicillamine or trientine, or zinc maintenance — remain highly effective when taken consistently. The medications overview page covers these in detail.

If you are managing Wilson disease well on current treatment, it is worth monitoring the trial landscape for future opportunities without disrupting a stable regimen. If your disease is poorly controlled despite treatment, that conversation with your specialist should happen first, before pinning hopes on a trial that may not yet be enrolling — or for which you may not qualify.

The WTX101 / bis-choline tetrathiomolybdate situation

This drug deserves a specific note because it generates significant patient interest and is sometimes described online as “new treatment” that sounds like gene therapy. It is not gene therapy — it is a new small-molecule copper chelator that works by forming a complex with copper and blocking its intestinal absorption and tissue uptake simultaneously, a different mechanism from penicillamine or trientine.⁴ Phase 2 data showed it was effective at reducing copper in newly diagnosed patients, with a tolerable side-effect profile.⁵ Whether it reaches approval and in which countries is something to monitor. Ask your specialist whether any trial or access programme for this drug is available in your region.

A word about “stem cell” and “CRISPR” claims online

Patients researching gene therapy for Wilson disease sometimes encounter websites or clinics advertising stem cell treatments or CRISPR-based cures, often at significant cost. These claims, particularly from unregulated commercial clinics, should be approached with great scepticism. No such treatment has been validated in peer-reviewed clinical trials for Wilson disease. Paying for unproven procedures is not only financially risky but may cause harm. Legitimate clinical trials do not charge patients for experimental treatment — they pay for the treatment and often provide compensation for participation.

The 2022 AASLD Practice Guidance notes that while gene therapy represents a promising future direction for Wilson disease, it remains investigational.⁷ Stick to registered trials at academic medical centres.

This page provides patient education only and is not medical advice. Whether to participate in a clinical trial is a serious decision that should be made with your specialist, after reviewing the trial’s eligibility criteria, potential risks, and what participation would require from you.

References